Wikidata entity: Q113896004
Quantities
| P2899 | minimum age | 18 |
| P31 | instance of | ... | Q30612 (clinical trial) | clinical trial |
| P4844 | research intervention | ... | Q50429626 (immunological antineoplastic agent) | immunological antineoplastic agent |
| P4844 | research intervention | ... | Q106957199 (amivantamab) | amivantamab |
| P4844 | research intervention | ... | Q619908 (alkylating antineoplastic agent) | alkylating antineoplastic agent |
| P8005 | research subject recruitment status | ... | Q92334785 (approved for marketing) | approved for marketing |
| P8363 | study type | ... | Q407954 (expanded access) | expanded access |
| P1476 | title | Monolingualtext | Pre-Approval Access With Amivantamab in Patients With Metastatic Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Who Have Failed Platinum-Based Chemotherapy | ??? |
| P3098 | ClinicalTrials.gov ID | NCT04599712 |
Why not click here or view trends?
log id: 3933554